Oxolife — Other · €2.5M

Oxolife received a €2.5M EIC Accelerator grant and is eligible for up to €10M of additional equity co-investment from the EIC Fund. It develops a non-hormonal oral tablet that prepares the endometrium to raise embryo implantation rates in IVF from today's 30-35% to over 50%.